Back to top

biotechnology: Archive

Zacks Equity Research

OTLK Stock Crashes 54% as FDA Issues Second CRL for Eye Disease Drug

Outlook Therapeutics stock plunges 54% after the FDA rejects ONS-5010 BLA again, citing lack of efficacy data in confirmatory study.

CRMDPositive Net Change KNSAPositive Net Change OTLKPositive Net Change PHARNegative Net Change

Ahan Chakraborty

Can Alnylam Rely on Amvuttra to Sustain Its Rapid Sales Momentum?

ALNY's Amvuttra revenues surge with 89% sales growth in H1 and a key label expansion, but faces tough competition in the ATTR-CM market.

ALNYPositive Net Change PFENegative Net Change BBIOPositive Net Change

Zacks Equity Research

INO Stock Soars as FDA Backs Rolling BLA for Rare Lung Disease Drug

Inovio stock surges 21% after the FDA gives green light to begin a rolling BLA for its RRP drug INO-3107, with plans to seek priority review.

INOPositive Net Change CRMDPositive Net Change KNSAPositive Net Change PGENPositive Net Change

Ahan Chakraborty

Novo Nordisk vs. Viking Therapeutics: Which GLP-1 Stock is a Safer Bet?

NVO and VKTX face setbacks and rising competition as they battle for ground in the GLP-1 obesity market.

NVONegative Net Change LLYPositive Net Change VKTXPositive Net Change

Ekta Bagri

Will Camzyos Strengthen BMY's Cardiovascular Portfolio?

Bristol Myers leans on Eliquis and surging Camzyos sales to offset looming generics, while its pipeline candidate milvexian readouts are near.

BMYNegative Net Change JNJPositive Net Change PFENegative Net Change CYTKNegative Net Change